A late-stage trial this week found that semaglutide (the drug sold as Ozempic for diabetes and Wegovy for obesity) lowered one of the main biological markers of Alzheimer's disease in spinal fluid. The exact numbers have not yet landed in detailed reporting, but the direction of the finding is clear: a drug already taken by millions of people for weight loss and diabetes may also do something useful in the brain.
In the same week, a peer-reviewed review in Drug Design, Development and Therapy ↗ mapped the state of peptide drugs for Alzheimer's. Peptides are short chains of amino acids, the same kind of molecule as semaglutide and insulin.
Three peptide classes already in Alzheimer's trials
The review names three specific directions the field is pursuing. The first is the GLP-1 drugs (the Ozempic family) being repurposed beyond diabetes and weight loss into Alzheimer's. The second is insulin sprayed directly into the nose, where it can reach the brain without needing to cross through the bloodstream. The third is oxytocin, the social-bonding hormone, also delivered as a nasal spray and being tested in early trials for Alzheimer's and related conditions.
The case for peptides in Alzheimer's, in simple terms
Most Alzheimer's drugs so far have fallen into two categories. There are the old symptom-covering memory medications that do not slow the disease. And there are the recent antibody drugs (like Leqembi and Kisunla) that attack the main plaque protein; these are expensive infusions with serious side-effect profiles.
Peptides offer something in the middle. They are cheaper and simpler than antibodies, more targeted than the older symptom drugs, and safer than most new chemicals. The hard part is getting them into the brain, because the brain has a barrier that blocks most molecules. The review catalogs the tricks now in use to get around it: making the peptide more stable so it survives longer, spraying it up the nose so it can reach the brain through nerve pathways, or attaching it to a delivery vehicle that can cross the barrier.
The caveats
None of this is a disease-modifying cure. The semaglutide signal is one trial substudy, and the detailed numbers are still pending. The review is a survey of the field, not a new trial. Everything in it is somewhere between early-stage and ongoing-trial.
A note from our side
Our platform hosts 204 candidates on the GLP-1 receptor, a handful on the insulin receptor, and entries on the oxytocin receptor too. The Alzheimer's review names these three as the front-line peptide modalities for the disease. That means card work on any of the three now has a direct Alzheimer's-relevance angle it did not have a year ago.
What to watch next
The detailed magnitude of the semaglutide brain-marker finding, once the peer-reviewed paper lands, will set the bar for how excited the field gets. A dedicated Alzheimer's trial of semaglutide is reportedly underway. If it produces a cognitive benefit, not just a biological marker change, the field's pace will visibly shift.